For older people and frail people, the long-term benefit of medicines reduces and the potential for harm from adverse effects increases. When the benefit–risk balance changes in this way, medicine review and optimisation are important to simplify the therapeutic regimen, reduce inappropriate medicines and minimise risks. In this article, pharmacist prescriber Linda Bryant uses two case studies to illustrate important considerations during medicine reviews
Pharmaceuticals, patients and politics: How has New Zealand got so far behind with medicines?
+Print Archive
Etcetera
Pharmaceuticals, patients and politics: How has New Zealand got so far behind with medicines?
Wednesday 14 April 2021, 12:50 AM

New Zealand takes 2.5 times the OECD average of nine months, to publicly fund modern medicines. Why the delay here? Asks Medicines New Zealand chief Graeme Jarvis
VIEWPOINT
Graeme Jarvis has some questions for the reviewers of funding agency Pharmac to ask as they embark on their work
The Government’s decision to have a review into drug funder Pharmac should be seen both as positive and as good public-sector governance.
This, of
Kia ora and welcome to New Zealand Doctor Rata Aotearoa
Not a subscriber? Unlock this article by subscribing here.